Table 1. Selected ongoing trials involving non-VEGF mediated pathways of angiogenesis.
Target | Drug | Malignancy | Phase | Trial |
---|---|---|---|---|
Angiopoietin/tie | ||||
AMG 386 | Ovarian | III | NCT01281254 | |
Ovarian | III | NCT01493505 | ||
Ovarian | III | NCT01204749 | ||
REGN-910 | Solid tumors | I | NCT01271972 | |
Solid tumors | I | NCT01688960 | ||
MEDI-3617 | Solid tumors | I | NCT01248949 | |
Dll4-notch | ||||
Demcizumab (OMP-21M18) | metastatic CRC | II | NCT01189942 | |
Pancreatic | II | NCT01189929 | ||
NSCLC | I | NCT01189968 | ||
MEDI0639 | Solid tumors | I | NCT01577745 | |
REGN-421 | Solid tumors | I | NCT00871559 | |
RO4929097 | NSCLC | II | NCT01193868 | |
Breast | I | NCT01071564 | ||
Sarcoma | I/II | NCT01154452 | ||
MK-0752 | Solid tumors | I | NCT01295632 | |
Pancreatic | I/II | NCT01098344 | ||
FGF (and VEGFR) | ||||
Brivanib | HCC | III | NCT00858871 | |
Metastatic CRC | I | NCT01046864 | ||
Nintedanib | Metastatic CRC | II | NCT01362361 | |
Endometrial | II | NCT01225887 | ||
Thyroid | II | NCT01788982 | ||
Ovarian | I | NCT01314105 | ||
AZD4547 | Gastric | II | NCT01457846 | |
NSCLC | I/II | NCT01824901 | ||
Solid tumors | I | NCT00979134 | ||
Dovitinib | Metastatic RCC | III | NCT01223027 | |
Glioblastoma | II | NCT01753713 | ||
Gastric | II | NCT01719549 | ||
Metastatic breast | II | NCT01262027 | ||
Castrate Resistant Prostate | II | NCT01741116 | ||
TGF-β | ||||
PF-03446962 | Urothelial | II | NCT01620970 | |
Solid tumors | I | NCT00557856 | ||
Solid tumors | I | NCT01337050 | ||
TRC105 | Metastatic breast I/II | NCT01326481 | ||
Glioblastoma | I/II | NCT01648348 | ||
Metastatic RCC | II | NCT01727089 | ||
Solid tumor | I | NCT01332721 | ||
LY2157299 | Glioblastoma | II | NCT01582269 | |
Pancreatic | I/II | NCT01373164 | ||
HCC | II | NCT01246986 | ||
HIF | ||||
EZN-2968 | Solid tumors | I | NCT01120288 |